糖皮质激素治疗重症社区获得性肺炎的疗效及对C反应蛋白水平的影响  

Clinical efficacy of glucocorticoids in the treatment of severe community acquired pneumonia and its impact on CRP

作　　者：隋东江[1] 张伟[1] 李伟生[1] 赵海霞[1] 王肇源[1] 

机构地区：[1]空军总医院干部病房3区,北京100142

出　　处：《临床肺科杂志》2013年第7期1171-1173,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察糖皮质激素治疗重症社区获得性肺炎(SCAP)的临床疗效及对血清CRP水平的影响。方法 60例SCAP患者随机分为治疗组和对照组。两组患者均给予常规治疗,治疗组在常规治疗的基础上给予糖皮质激素治疗。治疗前后测定患者血清CRP水平,连续治疗7d后评价疗效。结果治疗组临床疗效总有效率为83.3%,显著高于对照组(50.0%),相比较有显著性差异(P<0.05);治疗后,治疗组CRP水平下降,与治疗前和对照组比较均有显著性差异(P<0.05)。治疗组住院时间和再感染率显著下降,与对照组比较有显著性差异(P<0.05)。两组均无严重不良反应发生。结论糖皮质激素治疗SCAP能显著提高临床疗效,且安全可靠,并能影响CRP的释放,具有调节炎性反应的作用,值得临床推广应用。Objective To observe the clinical efficacy of glucocorticoids in the treatment of severe community acquired pneumonia （SCAP） and its impact on CRP. Methods 60 patients with SCAP were randomly divided into the treatment group and the control group. All patients were treated with the conventional therapy, and the treatment group was additionally treated with glucocorticoids. The level of CRP was detected before and after the treatment, and the clinical efficacy was evaluated 7 days after the treatment. Results The total ef- fective rate was 83.3% in the treatment group, which was significantly higher than that in the control group （50. % ） with significant difference （ χ2 = 7. 500, P 〈 0.05 ）. After the treatment, the level of CRP decreased more significantly in the treatment group than in the control group （ P 〈 0.05 ）. The duration of hospital stay and re - infection rate decreased more obviously in the treatment group than in the control group （ P 〈 0. 05 ）. There was no serious adverse events in the two groups. Conclusion Glucocorticoids can significantly improve the clinical efficacy in the treatment of patients with SCAP, affect the release of CRP, and regulate inflammatory response. It is a safe and reliable method and worthy of widely clinical application.

关 键 词：重症社区获得性肺炎 糖皮质激素 疗效观察 C反应蛋白 

分 类 号：R563.1[医药卫生—呼吸系统]